Trinity Capital Inc. Announces $15 Million Investment in Cagent Vascular Inc.
In an exciting development for the medical device sector, Trinity Capital Inc. (NASDAQ: TRIN), a prominent alternative asset manager, has made a significant commitment of $15 million in growth capital to Cagent Vascular Inc. This funding aims to support Cagent Vascular's innovative efforts in the development of vascular treatment technologies, particularly their advanced serration technology designed for vessel dilation within endovascular interventions.
Cagent Vascular's Innovative Approach
Cagent Vascular Inc. has established itself as a leader in medical device technology, especially with its flagship product, Serranator. This cutting-edge device enhances angioplasty procedures by yielding predictable and controlled lumen gain while minimizing dissection and vessel recoil. Cagent Vascular is dedicated to improving patient outcomes and advancing minimally invasive interventions through the development of advanced endovascular solutions.
Commitment to Patient-Centric Solutions
Ryan Kaeding, Managing Director of Life Sciences at Trinity Capital, expressed enthusiasm for the partnership, stating, "We are excited to partner with Cagent Vascular as they continue to innovate and expand their platform of valuable solutions for physicians treating patients with peripheral artery disease." This sentiment underscores Trinity Capital’s commitment to backing companies that prioritize patient care in their innovations.
Scaling Operations and Clinical Adoption
Brian Walsh, Chairman and CEO of Cagent Vascular, highlighted the impact of this funding by stating, "Cagent Vascular's Serration technology has been used in over 20,000 procedures and offers a growing library of compelling clinical evidence. We're confident this additional capital will help scale our commercial infrastructure and further accelerate clinical adoption." This showcases the importance of financial support in fostering growth and improving patient care.
About Trinity Capital Inc.
Trinity Capital Inc. is an international alternative asset manager with a distinct approach to investments, focusing on providing investors with stable and consistent returns. By gaining access to the private credit market, Trinity Capital sources, vets, and invests in dynamic privately funded growth-oriented companies, ultimately forming a strong and diversified portfolio.
A Trusted Partner for Growth
Headquartered in Phoenix, Arizona, Trinity Capital has cultivated a dedicated team of investment professionals strategically located to support its international operations. The firm is recognized as a trusted partner for innovative companies seeking tailored growth capital solutions.
About Cagent Vascular Inc.
Cagent Vascular Inc. was founded by a group of serial medical technology entrepreneurs and is recognized as the leader in Serration Technology for treating peripheral artery disease. The company's innovative approach to conventional angioplasty — which remains the most common procedure to restore blood flow — is aimed at transforming treatment outcomes for cardiovascular diseases.
Shaping the Future of Angioplasty
Despite angioplasty's longstanding use over the past 50 years, there is still considerable room for improvement. Cagent Vascular's mission focuses on addressing these opportunities, optimizing the therapy, and enhancing the overall patient experience. They are committed to the fight against peripheral artery disease (PAD) by continually innovating surgical solutions.
Frequently Asked Questions
What is the significance of the $15 million investment by Trinity Capital?
The $15 million investment aims to support Cagent Vascular's growth and innovation in developing advanced vascular treatment technologies.
How does the Serranator device improve angioplasty procedures?
The Serranator enhances angioplasty by providing predictable lumen gain with minimal dissection and controlling vessel recoil.
Who are the key executives involved in this partnership?
Ryan Kaeding is the Managing Director for Life Sciences at Trinity Capital, and Brian Walsh serves as the Chairman and CEO of Cagent Vascular.
What is Cagent Vascular's experience in the medical field?
Cagent Vascular has utilized its Serration technology in over 20,000 procedures and continues to build compelling clinical evidence for its effectiveness.
How does Trinity Capital benefit from investing in companies like Cagent Vascular?
Trinity Capital seeks stable and consistent returns by backing innovative companies like Cagent Vascular, which have the potential for substantial growth in the healthcare sector.
